BR112014012600A2 - sistema de produção de vetor lentiviral escalonável compatível com aplicações farmacêuticas industriais - Google Patents
sistema de produção de vetor lentiviral escalonável compatível com aplicações farmacêuticas industriaisInfo
- Publication number
- BR112014012600A2 BR112014012600A2 BR112014012600A BR112014012600A BR112014012600A2 BR 112014012600 A2 BR112014012600 A2 BR 112014012600A2 BR 112014012600 A BR112014012600 A BR 112014012600A BR 112014012600 A BR112014012600 A BR 112014012600A BR 112014012600 A2 BR112014012600 A2 BR 112014012600A2
- Authority
- BR
- Brazil
- Prior art keywords
- scalable
- production system
- lentiviral vector
- system compatible
- pharmaceutical applications
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 239000013598 vector Substances 0.000 title abstract 3
- 238000001415 gene therapy Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563566P | 2011-11-24 | 2011-11-24 | |
| EP11306551 | 2011-11-24 | ||
| PCT/EP2012/073645 WO2013076309A1 (en) | 2011-11-24 | 2012-11-26 | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014012600A2 true BR112014012600A2 (pt) | 2017-06-06 |
Family
ID=48469165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014012600A BR112014012600A2 (pt) | 2011-11-24 | 2012-11-26 | sistema de produção de vetor lentiviral escalonável compatível com aplicações farmacêuticas industriais |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20140315294A1 (en22) |
| EP (2) | EP2782997B1 (en22) |
| JP (2) | JP6280869B2 (en22) |
| CN (2) | CN109097398A (en22) |
| AU (1) | AU2012342355B2 (en22) |
| BR (1) | BR112014012600A2 (en22) |
| CA (1) | CA2856455C (en22) |
| CY (1) | CY1120103T1 (en22) |
| DK (1) | DK2782997T3 (en22) |
| ES (1) | ES2663815T3 (en22) |
| HR (1) | HRP20180424T1 (en22) |
| HU (1) | HUE036742T2 (en22) |
| LT (1) | LT2782997T (en22) |
| PL (1) | PL2782997T3 (en22) |
| PT (1) | PT2782997T (en22) |
| RS (1) | RS57066B1 (en22) |
| SG (1) | SG11201402584RA (en22) |
| SI (1) | SI2782997T1 (en22) |
| SM (1) | SMT201800174T1 (en22) |
| WO (1) | WO2013076309A1 (en22) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2782997B1 (en) | 2011-11-24 | 2018-01-10 | Genethon | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
| FR3010720B1 (fr) * | 2013-09-16 | 2017-08-11 | Genethon | Procede de production de virus enveloppes |
| FR3014901B1 (fr) | 2013-12-17 | 2017-06-09 | Genethon | Procede de purification de virus ou vecteurs viraux enveloppes |
| WO2015097650A1 (en) * | 2013-12-23 | 2015-07-02 | Theravectys | Lyophilized lentiviral vector particles, compositions and methods |
| GB201417042D0 (en) * | 2014-09-29 | 2014-11-12 | Fkd Therapies Oy | Method |
| EP4316500A3 (en) | 2015-05-13 | 2024-04-10 | CSL Behring Gene Therapy, Inc. | Bio-production of lentiviral vectors |
| CN105483092A (zh) * | 2015-10-10 | 2016-04-13 | 和元生物技术（上海）股份有限公司 | 一种中试化生产重组腺相关病毒的新技术 |
| SG11201806976UA (en) | 2016-02-23 | 2018-09-27 | Immune Design Corp | Multigenome retroviral vector preparations and methods and systems for producing and using same |
| CN109071594A (zh) * | 2016-04-14 | 2018-12-21 | 崔泽尔有限公司 | 具有恒流泵/管道系统的固定床生物反应器 |
| CN116144500A (zh) | 2016-04-14 | 2023-05-23 | 崔泽尔有限公司 | 具有恒流泵/管道系统的固定床生物反应器 |
| WO2018064584A1 (en) * | 2016-09-30 | 2018-04-05 | Life Technologies Corporation | Serum-free suspension system for lentiviral production |
| CN106867877A (zh) * | 2017-02-15 | 2017-06-20 | 昆明医科大学第二附属医院 | 一种密闭式慢病毒载体培养装置和培养方法 |
| US11674115B2 (en) | 2017-10-31 | 2023-06-13 | Global Life Sciences Solutions Usa Llc | Flexible bag |
| CN111727251B (zh) | 2017-11-21 | 2024-09-20 | 克里斯珀医疗股份公司 | 用于治疗常染色体显性色素性视网膜炎的材料和方法 |
| CA3084632A1 (en) | 2017-12-21 | 2019-06-27 | Crispr Therapeutics Ag | Materials and methods for treatment of usher syndrome type 2a |
| WO2019123430A1 (en) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
| CN110317832B (zh) | 2018-03-28 | 2022-07-05 | 西比曼生物科技（香港）有限公司 | Gmp级规模化制备重组慢病毒载体的纯化制剂的方法 |
| CN110317791A (zh) * | 2018-03-29 | 2019-10-11 | 西比曼生物科技（香港）有限公司 | Gmp级无血清悬浮细胞大规模生产慢病毒的方法 |
| CN108866013B (zh) * | 2018-08-06 | 2021-03-23 | 武汉赛科成科技有限公司 | 一种大规模生产慢病毒的方法 |
| EP3854879A4 (en) * | 2018-09-20 | 2022-06-22 | National University Corporation Tokyo Medical and Dental University | METHOD OF INCREASING THE PRODUCTION OF LENTIVIRUS VECTORS |
| CN109401969B (zh) * | 2018-12-13 | 2024-02-02 | 珠海西格膜生物技术有限公司 | 一种细胞工厂的管道连接系统及其使用方法 |
| JP7333930B2 (ja) * | 2019-01-07 | 2023-08-28 | 独立行政法人国立高等専門学校機構 | ミミズ細胞の保存方法及びミミズ培養細胞の形質転換方法 |
| JP2022551219A (ja) | 2019-08-23 | 2022-12-08 | ロンザ ウォーカーズヴィル，インコーポレーテッド | レンチウイルスベクターの製造方法および構築物 |
| CN113122501B (zh) * | 2019-12-30 | 2023-06-16 | 重庆精准生物技术有限公司 | 适合大规模临床级病毒载体制备的培养基及其应用 |
| JP2023526348A (ja) * | 2020-05-15 | 2023-06-21 | アイヴェックスソル インコーポレイテッド | 細胞療法及び遺伝子療法のための安定したウイルスベクター産生細胞を産生するための組成物及び方法 |
| US20230220417A1 (en) * | 2020-05-26 | 2023-07-13 | Expression Therapeutics, Llc | Lentiviral System |
| KR20230126214A (ko) * | 2020-12-29 | 2023-08-29 | 지앙수 젠스크립트 프로바이오 바이오테크 컴퍼니 리미티드 | 고분산성 hek293t 세포주 및 이의 스크리닝 방법 |
| GB202100688D0 (en) * | 2021-01-19 | 2021-03-03 | Autolus Ltd | Process |
| US20240425880A1 (en) * | 2021-10-12 | 2024-12-26 | Jiangsu Genscript Probio Biotech Co., Ltd. | Hek293 cell line adapted to serum-free suspension culture and use thereof |
| CA3231011A1 (en) * | 2021-10-19 | 2023-04-27 | Amgen Inc. | Composition and methods for recombinant lentiviral production |
| EP4508198A1 (en) * | 2022-04-11 | 2025-02-19 | Adverum Biotechnologies, Inc. | Optimization of hek293 suspension platform for improved raav titers |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| US6210922B1 (en) | 1998-11-30 | 2001-04-03 | National Research Council Of Canada | Serum free production of recombinant proteins and adenoviral vectors |
| US20030096414A1 (en) | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
| AU2002348151A1 (en) | 2001-11-05 | 2003-05-19 | Genvec, Inc. | Viral vector production methods and compositions |
| GB0702695D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
| EP2307551B1 (en) | 2008-06-18 | 2016-12-14 | Oxford BioMedica (UK) Limited | Purification of retroviral vectors |
| US20110008894A1 (en) | 2009-07-07 | 2011-01-13 | Cayla | Lyophilized plasmid/dna transfection reagent carrier complex |
| US8580554B2 (en) | 2009-07-31 | 2013-11-12 | Baxter International Inc. | Method of producing a polypeptide or virus of interest in a continuous cell culture |
| WO2011097447A2 (en) * | 2010-02-04 | 2011-08-11 | Neurologix, Inc. | Production of recombinant virus |
| CA2823639A1 (en) | 2011-01-05 | 2012-07-12 | Expression Therapeutics, Llc | High yield suspension cell line, system, and method for making same |
| EP2782997B1 (en) | 2011-11-24 | 2018-01-10 | Genethon | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
-
2012
- 2012-11-26 EP EP12795778.5A patent/EP2782997B1/en not_active Revoked
- 2012-11-26 JP JP2014542880A patent/JP6280869B2/ja not_active Expired - Fee Related
- 2012-11-26 AU AU2012342355A patent/AU2012342355B2/en not_active Ceased
- 2012-11-26 SI SI201231258T patent/SI2782997T1/en unknown
- 2012-11-26 US US14/359,960 patent/US20140315294A1/en not_active Abandoned
- 2012-11-26 HU HUE12795778A patent/HUE036742T2/hu unknown
- 2012-11-26 BR BR112014012600A patent/BR112014012600A2/pt not_active Application Discontinuation
- 2012-11-26 CN CN201810811238.0A patent/CN109097398A/zh active Pending
- 2012-11-26 RS RS20180365A patent/RS57066B1/sr unknown
- 2012-11-26 LT LTEP12795778.5T patent/LT2782997T/lt unknown
- 2012-11-26 EP EP17210574.4A patent/EP3327119A1/en not_active Withdrawn
- 2012-11-26 CN CN201280058157.9A patent/CN104136605B/zh not_active Expired - Fee Related
- 2012-11-26 PL PL12795778T patent/PL2782997T3/pl unknown
- 2012-11-26 SG SG11201402584RA patent/SG11201402584RA/en unknown
- 2012-11-26 PT PT127957785T patent/PT2782997T/pt unknown
- 2012-11-26 HR HRP20180424TT patent/HRP20180424T1/hr unknown
- 2012-11-26 DK DK12795778.5T patent/DK2782997T3/en active
- 2012-11-26 CA CA2856455A patent/CA2856455C/en active Active
- 2012-11-26 ES ES12795778.5T patent/ES2663815T3/es active Active
- 2012-11-26 SM SM20180174T patent/SMT201800174T1/it unknown
- 2012-11-26 WO PCT/EP2012/073645 patent/WO2013076309A1/en active Application Filing
-
2017
- 2017-10-05 JP JP2017195148A patent/JP2018046828A/ja active Pending
-
2018
- 2018-03-30 CY CY20181100358T patent/CY1120103T1/el unknown
-
2019
- 2019-03-18 US US16/356,005 patent/US20190211360A1/en not_active Abandoned
-
2021
- 2021-09-02 US US17/464,727 patent/US20220235371A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2663815T3 (es) | 2018-04-17 |
| CN104136605B (zh) | 2018-08-14 |
| EP2782997A1 (en) | 2014-10-01 |
| CN109097398A (zh) | 2018-12-28 |
| EP3327119A1 (en) | 2018-05-30 |
| CA2856455C (en) | 2022-08-23 |
| SG11201402584RA (en) | 2014-06-27 |
| JP2018046828A (ja) | 2018-03-29 |
| SI2782997T1 (en) | 2018-04-30 |
| DK2782997T3 (en) | 2018-04-16 |
| JP6280869B2 (ja) | 2018-02-14 |
| PL2782997T3 (pl) | 2018-06-29 |
| WO2013076309A1 (en) | 2013-05-30 |
| RS57066B1 (sr) | 2018-06-29 |
| LT2782997T (lt) | 2018-05-25 |
| HRP20180424T1 (hr) | 2018-06-29 |
| CA2856455A1 (en) | 2013-05-30 |
| JP2014533516A (ja) | 2014-12-15 |
| US20220235371A1 (en) | 2022-07-28 |
| AU2012342355A1 (en) | 2014-07-17 |
| US20190211360A1 (en) | 2019-07-11 |
| EP2782997B1 (en) | 2018-01-10 |
| CN104136605A (zh) | 2014-11-05 |
| SMT201800174T1 (it) | 2018-07-17 |
| AU2012342355B2 (en) | 2017-10-12 |
| PT2782997T (pt) | 2018-04-09 |
| US20140315294A1 (en) | 2014-10-23 |
| CY1120103T1 (el) | 2018-12-12 |
| HUE036742T2 (hu) | 2018-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014012600A2 (pt) | sistema de produção de vetor lentiviral escalonável compatível com aplicações farmacêuticas industriais | |
| WO2014057432A3 (en) | Multicomponent lipid nanoparticles and processes for the preparation thereof | |
| MX2018013981A (es) | Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina. | |
| BR112018075479A2 (pt) | portadores híbridos para carga de ácido nucleico | |
| MX344219B (es) | Productos farmaceuticos peptidicos mejorados para resistencia a insulina. | |
| GT200900121A (es) | Moleculas de enlace de lingo y uso farmaceutico | |
| BR112014030009A2 (pt) | polipeptídeos que têm atividade de transgalactosilação | |
| BR112013030824A8 (pt) | Bactéria gram-positiva, ácido necleico recombinante, composição farmacêutica e vetor | |
| WO2013177231A8 (en) | Translocation of non-natural chemical entities through anthrax protective antigen pore | |
| BR112013030963A2 (pt) | proteína de fusão, polinucleotídio, constructo, vetor, célula hospedeira ou organismo, composição farmacêutica ou vacina, uso da proteína de fusão, método para prevenir ou tratar infecção hev ou doenças associadas com infecção hev, método para prevenir ou tratar infecção do vírus influenza e doenças associadas com a infecção do vírus influenza, método para melhorar a imunogenicidade de uma proteína alvo e uso de crm197 ou um fragmento do mesmo | |
| WO2013170170A3 (en) | Compositions and methods for gene therapy | |
| TR201908550T4 (tr) | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. | |
| MX352205B (es) | Sistemas de expresion. | |
| EP2924052A4 (en) | DOUBLE-TARGET ANTIBODIES FOR TARGETING VEGFR-2 AND DLL4 AND PHARMACEUTICAL COMPOSITION THEREWITH | |
| BR112015024605A2 (pt) | sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo | |
| BR112013007862A2 (pt) | ácidos nucleicos manipulados e métodos de uso dos mesmos. | |
| WO2013028942A8 (en) | Targeting microbubbles | |
| BR112019004594A2 (pt) | terapia genética para pacientes com anemia de fanconi | |
| ZA201504353B (en) | Chain-extending poloxamers, thermoreversible hydrogels formed by them which include biological materials, and medicinal applications of same | |
| BR112014022214A2 (pt) | fenólicos antibacterianos | |
| PH12015502096B1 (en) | Thymidine kinase diagnostic assay for gene therapy applications | |
| BR112013006299A2 (pt) | microdispositivo para aplicações num sistema biológico, métodos de utilização de um microdispositivo, e para distribuição de múltiplas doses de medicamento a uma localização alvo, e, microdispositivo para aplicação fora do sistema biológico | |
| MX384236B (es) | Productos farmaceuticos mejorados de peptido para resistencia a la insulina | |
| MX2014002062A (es) | Nanoparticulas de peptido y usos de las mismas. | |
| BR112014021497A2 (pt) | sistema de entrega de fármaco baseado em jcv-vlp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |